Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (241-250 of 300) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)Wilfried Ernst Erich Eberhardt, Christoph Pöttgen, Thomas Christoph Gauler, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 23, 2022
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implicationsMatthias Scheffler, Marcel Wiesweg, Sebastian Michels, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Theranostics|September 23, 2024
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of <sup>68</sup>Ga-SSO120 PET with immunohistochemistry and survivalIlektra Antonia Mavroeidi, Anna Romanowicz, Tristan Haake, et al.
The New Phytologist|June 15, 2023
A phloem-localized Arabidopsis metacaspase (AtMC3) improves drought toleranceEugenia Pitsili, Ricardo Rodriguez-Trevino, Nerea Ruiz-Solani, et al.
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.
Pageof 30

Showing results (241-250 of 300) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)Wilfried Ernst Erich Eberhardt, Christoph Pöttgen, Thomas Christoph Gauler, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 23, 2022
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implicationsMatthias Scheffler, Marcel Wiesweg, Sebastian Michels, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Theranostics|September 23, 2024
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of <sup>68</sup>Ga-SSO120 PET with immunohistochemistry and survivalIlektra Antonia Mavroeidi, Anna Romanowicz, Tristan Haake, et al.
The New Phytologist|June 15, 2023
A phloem-localized Arabidopsis metacaspase (AtMC3) improves drought toleranceEugenia Pitsili, Ricardo Rodriguez-Trevino, Nerea Ruiz-Solani, et al.
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.
Pageof 30